NCT06131580View on ClinicalTrials.gov

Canadian Continuation of Roll-over Study in Patients With Endogenous Cushing's Syndrome

PHASE4Active, not recruitingINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

October 24, 2023

Primary Completion Date

November 24, 2025

Study Completion Date

November 24, 2025

Conditions
Endogenous Cushing Syndrome
Interventions
DRUG

Intervention/Treatment

"Drug: osilodrostat~\- osilodrostat, in the form of film coated tablets for oral administration, in the following tablet strengths: 1mg, 5mg, 10mg. Each strength has unique tablet size, colour and imprint."

Trial Locations (3)

T6G 2E1

University of Alberta Hospital - Alberta Diabetes Institute, Edmonton

B3H 1V7

Nova Scotia Health, Halifax

J1H 5N4

CHUS Sherbrooke, Sherbrooke

All Listed Sponsors
collaborator

Recordati Rare Diseases

INDUSTRY

lead

Centre hospitalier de l'Université de Montréal (CHUM)

OTHER

NCT06131580 - Canadian Continuation of Roll-over Study in Patients With Endogenous Cushing's Syndrome | Biotech Hunter | Biotech Hunter